Through education, consensus building  and advocacy, the Best Medicines Coalition addresses issues related to pharmaceutical regulatory review, assessment, reimbursement and supply Coalition positions are communicated to policy decision makers and stakeholders in a range of ways including through submissions to formal consultations, representation on advisory bodies, development and distribution of position documents, correspondence, meetings and presentations.

Pharmacare & Pharmaceutical Reform

We support reforms which will allow  all Canadians to access the medicines they need when needed, equitably and consistently, as outlined in our core positions and principles, and in formal submissions.
CADTH Advisory Panel:
BMC Submission on Potential Pan-Canadian Formulary (February 25, 2022)

National Strategy for Drugs for Rare Diseases:
BMC’s Submission on the National Strategy for Drugs for Rare Diseases — Additional Considerations (August 15, 2022)

BMC’s Submission on the National Strategy for Drugs for Rare Diseases (March 26, 2021)

Pharmacare Advisory Council:
BMC’s Position Points on Key Recommendations (July 2019)

Statement Regarding National Pharmacare Interim Report Announcement (March 6, 2019)

Positions and Considerations Regarding National Pharmacare Funding Options (January 2019)

National Pharmacare Implementation: Patient Perspectives and Considerations (September 2018)

BMC Survey:
Patient Perspectives on National Pharmacare: Current Challenges, Goals and Implementation Issues (August 2018)

BMC Positions:
Federal Health Mandate: Put patient values, needs and improved outcomes at the centre of health and pharmaceutical policy (November 15, 2021)

Submission to the House of Commons Standing Committee on Finance (August 2020)

Pharmacare Position Points (September 2019)

Principles & Considerations Regarding Pharmacare (2016)

Submission: Standing Committee on Health (October 18, 2017)

Joint Discussion Paper:
Better Pharmacare For Patients: Evaluating Policy Options (June 2018) (Français)

Pharmaceutical Pricing

We support a strong regulatory framework for pharmaceutical pricing which ensures value and an environment which delivers the best possible care for patients.
BMC Positions:
PMPRB 2022 Draft Guidelines Consultation (December 5, 2022)

Submission to Finance Canada: Priorities for the Federal Budget (February 25, 2022)

Federal Health Mandate: Put patient values, needs and improved outcomes at the centre of health and pharmaceutical policy (November 15, 2021)

Input to PMPRB Regarding Proposed Guideline Revisions Related to Gap Medicines, Comparator Countries and International Price Tests (August 31, 2021)

Input Regarding PMPRB Proposed Guideline Monitoring and Evaluation Plan (June 21, 2021)

Letter Responding to PMPRB Board Chair (June 8, 2021) (français)

Letter to the Prime Minister Regarding PMPRB (May 28, 2021) (français)

Submission to the Standing Committee on Health: PMPRB Guidelines (November 6, 2020) (français)

Letter to the Minister of Health (August 10, 2020) (français)

Submission to the House of Commons Standing Committee on Finance (August 2020)

Submission Regarding PMPRB Revised Draft Guidelines (August 2020) (français)

Letter to the Minister of Health (June 19, 2020) (français)

Submission to the House of Commons Standing Committee on Health (May 2020)

Submission Regarding Draft Guidelines to Implement the Patented Medicines Regulations, as amended (February 2020)

Letter to Health Canada Regarding Proposed Patented Medicines Regulations (February 2018)

Submission Regarding PMPRB Modernization (October 2016)